MINT-FENOFIBRATE E TABLET
Страна: Канада
Език: английски
Източник: Health Canada
Данни за продукта
(SPC)
23-06-2017
Понастоящем някои документи за този продукт не са налични, можете да изпратите заявка до нашата служба за клиенти и ние ще ви уведомим веднага щом успеем да ги получим.
Изпрати заяв.
Изпрати заяв.
Активна съставка:
FENOFIBRATE
Предлага се от:
MINT PHARMACEUTICALS INC
АТС код:
C10AB05
INN (Международно Name):
FENOFIBRATE
дозиране:
145MG
Лекарствена форма:
TABLET
Композиция:
FENOFIBRATE 145MG
Начин на приложение:
ORAL
Броя в опаковка:
90
Вид предписание :
Prescription
Терапевтична област:
FRIBIC ACID DERIVATIVES
Каталог на резюме:
Active ingredient group (AIG) number: 0118895006; AHFS:
Статус Оторизация:
CANCELLED POST MARKET
Дата Оторизация:
2020-04-28
Данни за продукта
PRODUCT MONOGRAPH
Pr
MINT-FENOFIBRATE E
fenofibrate
film-coated tablets (145 mg)
USP
LIPID METABOLISM REGU
LATOR
Mint Pharmaceuticals Inc.
Date of Preparation:
1093 Meyerside Dr., Unit #1
JUNE 15, 2017
Mississauga, Ontario
L5T 1J6
Submission Control No: 186636
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3
SUMMARY PRODUCT
INFORMATION.........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
....................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
..................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
14
DOSAGE AND ADMINISTRATION
..............................................................................
18
OVERDOSAGE
.................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 19
STORAGE AND STABILITY
..........................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 21
PART II: SCIENTIFIC INFORMATION
........................................................................
23
PHARMACEUTICAL INFORMATION
..........................................................................
23
CLINICAL TRIALS
..........................................................................................................
24
DETAILED PHARMACOLOGY
.....................................................................................
29
TO
Прочетете целия документ
